TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
The Chinese biotech said the enrollment marks a key milestone for its advancing bile duct cancer treatment By Teri Yu Clinical-stage biotech firm TransThera Sciences (Nanjing) Inc. (2617.HK) said it…
A wild ride for TransThera investors: what’s the story?
The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
TransThera seeks Hong Kong IPO to sustain cancer drug research
The developer of drugs for advanced or recurrent cancers has already conducted nine financing rounds, but will not start generating commercial revenue before 2026, as all its products are still…
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
- Investors pile onto TenNor IPO with hopes for new type of gastric drug
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
- A healthy return: drug spin-off nets Keymed up to $320 million
- Eye drug maker VivaVision feels the strain in IPO funding dash
- Mega licensing deal lifts 3SBio profits but core sales slip
